You are here: Industry Insights > Market News > Granules India posts Q2 net profit at Rs 40 crore

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Vibegron Intermediate CAS:1421271-01-3

Food Grade Fish Collagen

Vibegron Intermediate CAS:1295539-30-8

Vibegron Intermediate CAS:1426235-01-9

Vibegron Intermediate CAS:163625-46-5

Vibegron Intermediate

Granules India posts Q2 net profit at Rs 40 crore

expressbpdNovember 10, 2017

Tag: granules , net profit , India

Favorites

Total income during the quarter under review stood at Rs 399.39 crore

Granules India has reported almost flat consolidated net profit at Rs 40.33 crore for the September quarter of the current fiscal.

The company had posted a net profit of Rs 40.82 crore during the same period of the previous fiscal, Granules India said in a regulatory filing.

Total income during the quarter under review stood at Rs 399.39 crore as against Rs 367.68 crore in the July-September quarter of the last fiscal.

"As our emerging business is taking shape to drive future business growth, our core business continues to deliver sustainable revenues," Krishna Prasad Chigurupati, CMD, Granules India said.

Previous:Nanoshells could deliver more chemo with fewer side effects

Next:Morepen Labs ties up with Vesale Pharma

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Granules India posts Q2 net profit at Rs 40 crore | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Diminazene aceturate and Phenazone and Vitamin B granules for injection

Diminazene aceturate and Phenazone granules for injection

Evening Primrose Oil (OEM/ODM) | Evening Primrose Oil From India / natural Evening Prim rose Oil

100% Pure Freeze Dried Black Berry Anthocyanin Juice Indian Instant Fruit Blackberry Powder

Factory Free Sample Bulk Food Pure Grade Natural India Herbal Plant Extract Madder Root Extract

Azithromycin Granules 100mg, 250mg

Hot Melt Extruder Machine Twin Screw Plastic Granules Making Machine Double-sxrew Extruder Pharmaceu

1,3-dibromo-5,5-dimethylhydantoin DBDMH Granules CAS NO.77-48-5

Naproxen Enteric_coated micro Granules Capsules

1-bromo-3-chloro-5,5-dimethylhydantoin Granules BCDMH CAS NO. 32718-18-6

Granules India posts Q2 net profit at Rs 40 crore

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>